Nanoparticle-aptamer bioconjugates for cancer targeting

Expert Opinion on Drug Delivery

Volumn 3, Issue 3, 2006, Pages 311-324

  Farokhzad, Omid C ^a   Karp, Jeffrey M ^b   Langer, Robert ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Aptamer; Cancer therapy; Controlled release; In vitro selection; Nanoparticles; SELEX; Targeted drug delivery

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APTAMER; CELL PROTEIN; DENILEUKIN DIFTITOX; EPIDERMAL GROWTH FACTOR RECEPTOR 3; LIGAND; NANOPARTICLE; NUCLEIC ACID; NUCLEOLIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; POLYMER; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RITUXIMAB; SIALYL LEWIS X ANTIGEN; T LYMPHOCYTE ANTIGEN; TENASCIN;

B CELL LYMPHOMA; BIOCHEMISTRY; CANCER CELL; CANCER THERAPY; CELL MEMBRANE; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENCAPSULATION; HUMAN; HYDROPHILICITY; METASTASIS POTENTIAL; NONHODGKIN LYMPHOMA; NONHUMAN; PHOTODYNAMIC THERAPY; REVIEW; RNA INTERFERENCE; T CELL LYMPHOMA;

ANIMALS; APTAMERS, NUCLEOTIDE; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; NANOSTRUCTURES; NEOPLASMS; SELEX APTAMER TECHNIQUE; SURFACE PROPERTIES;

EID: 33646851877     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.3.3.311     Document Type: Review

References (111)

1. FERRARI M: Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer (2005) 5:161-171.
2. LANGER R, TIRRELL DA: Designing materials for biology and medicine. Nature (2004) 428:487-492.
3. ANDERSON DG, PENG W, AKINC A et al.: A polymer library approach to suicide gene therapy for cancer. Proc. Natl. Acad. Sci. USA (2004) 101:16028-16033.
4. SULLENGER BA, GALLARDO HF, UNGERS GE, GILBOA E: Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell (1990) 63:601-608.
5. ELLINGTON AD, SZOSTAK JW: In vitro selection of RNA molecules that bind specific ligands. Nature (1990) 346:818-822.
6. TUERK C, GOLD L: Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (1990) 249:505-510.
7. JAMES JS, DUBS G: FDA approves new kind of lymphoma treatment. Food and Drug Administration. AIDS Treat. News (1997) 284:2-3.
8. FOSS FM: DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin. Lymphoma (2000) 1:110-116.
9. MARKS JD: Selection of internalizing antibodies for drug delivery. Methods Mol. Biol. (2004) 248:201-208.
10. MARKS JD, OUWEHAND WH, BYE JM et al: Human antibody fragments specific for human blood group antigens from a phage display library. Biotechnology (1993) 11:1145-1149.
11. DOGGRELL SA: Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration. Expert Opin. Pharmacother. (2005) 6:1421-1423.
12. HICKE BJ, STEPHENS AW: Escort aptamers: a delivery service for diagnosis and therapy. J. Clin. Invest. (2000) 106:923-928.
13. FAROKHZAD OC, JON S, KHADEMHOSSEINI A, TRAN TN, LAVAN DA, LANGER R: Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. (2004) 64:7668-7672.
14. FAROKHZAD OC, CHENG J, TEPLY BA et al.: Targeted nanoparticle-aptamer bioconjugates result in significant tumor reduction in vivo. Proc. Natl. Acad. Sci. USA (2006). In press.
15. WHITE RR, SULLENGER BA, RUSCONI CP: Developing aptamers into therapeutics. J. Clin. Invest. (2000) 106:929-934.
16. DROLET DW, NELSON J, TUCKER CE et al.: Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm. Res. (2000) 17:1503-1510.
17. HERMANN T, PATEL DJ: Adaptive recognition by nucleic acid aptamers. Science (2000) 287:820-825.
18. WILSON DS, SZOSTAK JW: In vitro selection of functional nucleic acids. Ann. Rev. Biochem. (1999) 68:611-647.
19. JENISON RD, GILL SC, PARDI A, POLISKY B: High-resolution molecular discrimination by RNA. Science (1994) 263:1425-1429.
20. TOMBELLI S, MINUNNI M, MASCINI M: Analytical applications of aptamers. Biosens. Bioelectron. (2005) 20:2424-2434.
21. CHARLTON J, SENNELLO J, SMITH D: In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase. Chem. Biol. (1997) 4:809-816.
22. BEIGELMAN L, MCSWIGGEN JA, DRAPER KG et al.: Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J. Biol. Chem. (1995) 270:25702-25708.
23. AURUP H, WILLIAMS DM, ECKSTEIN F: 2′-Fluoro- and 2′-amino-2′-deoxynucleoside 5′-triphosphates as substrates for T7 RNA polymerase. Biochemistry (1992) 31:9636-9641.
24. PIEKEN WA, OLSEN DB, BENSELER F, AURUP H, ECKSTEIN F: Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes. Science (1991) 253:314-317.
25. EULBERG D, KLUSSMANN S: Spiegelmers: biostable aptamers. Chembiochem. (2003) 4:979-983.
26. SCHMIDT KS, BORKOWSKI S, KURRECK J et al.: Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res. (2004) 32:5757-5765.
27. BOOMER RM, LEWIS SD, HEALY JM, KURZ M, WILSON C, MCCAULEY TG: Conjugation to polyethylene glycol polymer promotes aptamer biodistribution to healthy and inflamed tissues. Oligonucleotides (2005) 15:183-195.
28. HEALY JM, LEWIS SD, KURZ M et al.: Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm. Res. (2004) 21:2234-2246.
29. GERMAN I, BUCHANAN DD, KENNEDY RT: Aptamers as ligands in affinity probe capillary electrophoresis. Anal. Chem. (1998) 70:4540-4545.
30. CHAN WC, NIE S: Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science (1998) 281:2016-2018.
31. HARISINGHANI MG, BARENTSZ J, HAHN PF et al.: Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. (2003) 348:2491-2499.
32. BONNEMAIN B: Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A review. J. Drug Target. (1998) 6:167-174.
33. WEISSLEDER R: Scaling down imaging: molecular mapping of cancer in mice. Nat. Rev. Cancer (2002) 2:11-18.
34. PESTOURIE C, TAVITIAN B, DUCONGE F: Aptamers against extracellular targets for in vivo applications. Biochimie (2005) 87:921-930.
35. CHEN CH, CHERNIS GA, HOANG VQ, LANDGRAF R: Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc. Natl. Acad. Sci. USA (2003) 100:9226-9231.
36. 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J. Clin. Oncol. (2005) 23:4591-4601.
37. LUPOLD SE, HICKE BJ, LIN Y, COFFEY DS: Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. (2002) 62:4029-4033.
38. DENG JS, BALLOU B, HOFMEISTER JK: Internalization of anti-nucleolin antibody into viable HEp-2 cells. Mol. Biol. Rep. (1996) 23:191-195.
39. CHRISTIAN S, PILCH J, AKERMAN ME, PORKKA K, LAAKKONEN P, RUOSLAHTI E: Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J. Cell Biol. (2003) 163:871-878.
40. DAPIC V, ABDOMEROVIC V, MARRINGTON R et al.: Biophysical and biological properties of quadruplex oligodeoxyribonucleotides. Nucleic Acidc Res. (2003) 31:2097-2107.
41. BARNHART KM, LABER DA, BATES PJ, TRENT JO, MILLER DM; AGRO100: The translation from lab to clinic of a tumor-targeted nucleic acid aptamer. J. Clin. Oncol. (2004) 22(14S):Abstract 3126.
42. LABER DA, SHARMA VR, BHUPALAM L, TAFT B, HENDLER FJ, BARNHART KM: Update on the first Phase I study of AGRO100 in advanced cancer. J. Clin. Oncol. (2005) 23(16S):Abstract 3064.
43. JEONG S, EOM T, KIM S, LEE S, YU J: In vitro selection of the RNA aptamer against the Sialyl Lewis X and its inhibition of the cell adhesion. Biochem. Biophys. Res. Commun. (2001) 281:237-243.
44. SANTULLI-MAROTTO S, NAIR SK, RUSCONI C, SULLENGER B, GILBOA E: Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res. (2003) 63:7483-7489.
45. HICKE BJ, MARION C, CHANG YF et al.: Tenascin-C aptamers are generated using tumor cells and purified protein. J. Biol. Chem. (2001) 276:48644-48654.
46. PIETRAS K, RUBIN K, SJOBLOM T et al.: Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. (2002) 62:5476-5484.
47. PIETRAS K, OSTMAN A, SJOQUIST M et al.: Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. (2001) 61:2929-2934.
48. BLANK M, WEINSCHENK T, PRIEMER M, SCHLUESENER H: Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels. selective targeting of endothelial regulatory protein pigpen. J. Biol. Chem. (2001) 276:16464-16468.
49. FITZWATER T, POLISKY B: A SELEX primer. Methods Enzymol. (1996) 267:275-301.
50. CHELLISERRYKATTIL J, ELLINGTON AD: Evolution of a T7 RNA polymerase variant that transcribes 2′-O-methyl RNA. Nat. Biotechnol. (2004) 22:1155-1160.
51. BURMEISTER PE, LEWIS SD, SILVA RF et al.: Direct in vitro selection of a 2′-O-methyl aptamer to VEGF. Chem. Biol. (2005) 12:25-33.
52. LANGER R: Drug delivery and targeting. Nature (1998) 392:5-10.
53. SANTINI JT Jr, CIMA MJ, LANGER R: A controlled-release microchip. Nature (1999) 397:335-338.
54. EDWARDS DA, HANES J, CAPONETTI G et al.: Large porous particles for pulmonary drug delivery. Science (1997) 276:1868-1871.
55. LAVAN DA, MCGUIRE T, LANGER R: Small-scale systems for in vivo drug delivery. Nat. Biotechnology (2003) 21:1184-1191.
56. ELISSEEFF J, MCINTOSH W, FU K, BLUNK BT, LANCER R: Controlled-release of IGF-1 and TGF-β1 in a photopolymerizing hydrogel for cartilage tissue engineering. J. Orthop. Res. (2001) 19:1098-1104.
57. TANABE K, REGAR E, LEE CH, HOYE A, VAN DER GIESSEN WJ, SERRUYS PW: Local drug delivery using coated stents: new developments and future perspectives. Curr. Pharm. Des. (2004) 10:357-367.
58. EBRAHIM S, PEYMAN GA, LEE PJ: Applications of liposomes in ophthalmology. Surv. Ophthalmol. (2005) 50:167-182.
59. HAAK T: New developments in the treatment of Type 1 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes (1999) 107(Suppl. 3):S108-S113.
60. GUERIN C, OLIVI A, WEINGART JD, LAWSON HC, BREM H: Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest. New Drugs (2004) 22:27-37.
61. JIANG W, GUPTA RK, DESHPANDE MC, SCHWENDEMAN SP: Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv. Drug Deliv. Rev. (2005) 57:391-410.
62. TAKAHIRA N, ITOMAN M, HIGASHI K, UCHIYAMA K, MIYABE M, NARUSE K: Treatment outcome of two-stage revision total hip arthroplasty for infected hip arthroplasty using antibiotic-impregnated cement spacer. J. Orthop. Sci. (2003) 8:26-31.
63. LYNN DM, AMIJI MM, LANGER R: pH-responsive polymer microspheres: rapid release of encapsulated material within the range of intracellular pH. Angew Chem. Int. Ed. Engl. (2001) 40:1707-1710.
64. LENDLEIN A, JIANG H, JUNGER O, LANGER R: Light-induced shape-memory polymers. Nature (2005) 434:879-882.
65. LENDLEIN A, LANGER R: Biodegradable, elastic shape-memory polymers for potential biomedical applications. Science (2002) 296: 1673-1676.
66. ZION TC, YING JY: Glucose responsive nanoparticle for controlled insulin delivery. Materials Research Society Fall Meeting, Boston, MA, USA (2003).
67. GREF R, MINAMITAKE Y, PERACCHIA MT, TRUBETSKOY V, TORCHILIN V, LANGER R: Biodegradable long-circulating polymeric nanospheres. Science (1994) 263:1600-1603.
68. BALA I, HARIHARAN S, KUMAR MN: PLGA nanoparticles in drug delivery: the state of the art. Crit. Rev. Ther. Drug Carrier Syst. (2004) 21:387-422.
69. DROTLEFF S, LUNGWITZ U, BREUNIG M et al.: Biomimetic polymers in pharmaceutical and biomedical sciences. Eur. J. Pharm. Biopharm (2004) 58:385-407.
70. MOGHIMI SM, HUNTER AC, MURRAY JC: Nanomedicine: current status and future prospects. FASEB J. (2005) 19:311-330.
71. PANYAM J, LABHASETWAR V: Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. (2003) 55:329-347.
72. RAVI KUMAR M, HELLERMANN G, LOCKEY RF, MOHAPATRA SS: Nanoparticle-mediated gene delivery: state of the art. Expert Opin. Biol. Ther. (2004) 4:1213-1224.
73. MAEDA H, WU J, SAWA T, MATSUMURA Y, HORI K: Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release (2000) 65:271-284.
74. BRIGGER I, DUBERNET C, COUVREUR P: Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. (2002) 54:631-651.
75. LIU D, MORI A, HUANG L: Role of liposome size and RES blockade in controlling biodistriburion and tumor uptake of GM1-containing liposomes. Biochim. Biophys. Acta (1992) 1104:95-101.
76. ALONSO MJ, GUPTA RK, MIN C, SIBER GR, LANGER R: Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine (1994) 12:299-306.
77. DAVDA J, LABHASETWAR V: Characterization of nanoparticle uptake by endothelial cells. Int. J. Pharm. (2002) 233:51-59.
78. DENG JS, LI L, TIAN Y, GINSBURG E, WIDMAN M, MYERS A: In vitro characterization of polyorthoester microparticles containing bupivacaine. Pharm. Dev. Technol. (2003) 8:31-38.
79. MOLPECERES J, CHACON M, GUZMAN M, BERGES L, DEL ROSARIO ABERTURAS M: A polycaprolactone nanoparticle formulation of cyclosporin-A improves the prediction of area under the curve using a limited sampling strategy. Int. J. Pharm. (1999) 187:101-113.
80. SOMMERFELD P, SABEL BA, SCHROEDER U: Long-term stability of PBCA nanoparticle suspensions. J. Microencapsul. (2000) 17:69-79.
81. GAO J, NIKLASON L, ZHAO XM, LANGER R: Surface modification of polyanhydride microspheres. J. Pharm. Sci. (1998) 87:246-248.
82. HUANG G, GAO J, HU Z, ST JOHN JV, PONDER BC, MORO D: Controlled drug release from hydrogel nanoparticle networks. J. Control. Release (2004) 94:303-311.
83. ROSCA ID, WATARI F, UO M: Micropartide formation and its mechanism in single and double emulsion solvent evaporation. J. Control. Release (2004) 99:271-280.
84. BILATI U, ALLEMANN E, DOELKER E: Poly(D,L-lactide-co-glycolide) protein-loaded nanoparticles prepared by the double emulsion method-processing and formulation issues for enhanced entrapment efficiency. J. Microencapsul. (2005) 22:205-214.
85. BILATI U, ALLEMANN E, DOELKER E: Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J. Pharm. Sci. (2005) 24:67-75.
86. CHORNY M, FISHBEIN I, DANENBERG HD, GOLOMB G: Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J. Control. Release (2002) 83:389-400.
87. LANGER R: Drug delivery. Drugs on target. Science (2001) 293:58-59.
88. LANGER R, PEPPAS NA: Advances in biomaterials, drug delivery, and bionanotechnology. AIChE J. (2003) 49:2990-3006.
89. MATSUSUE Y, HANAFUSA S, YAMAMURO T, SHIKINAMI Y, IKADA Y: Tissue reaction of bioabsorbable ultra high strength poly(L-lactide) rod. A long-term study in rabbits. Clin. Orthop. Relat. Res. (1995) 317:246-253.
90. CHONN A, CULLIS PR, DEVINE DV: The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J. Immunol. (1991) 146:4234-4241.
91. CAMPBELL RB, FUKUMURA D, BROWN EB et al.: Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. (2002) 62:6831-6836.
92. JAFFAR S, NAM KT, KHADEMHOSSEINI A, XING J, LANGER R, BELCHER AM: Layer-by-layer surface modification and patterned electrodeposition of quantum dots. Nano Lett. (2004) 4:1421-1425.
93. FAROKHZAD OC, KHADEMHOSSEINI A, JON S et al.: Microfluidic system for studying the interaction of nanoparticles and microparticles with cells. Anal. Chem. (2005) 77:5453-5459.
94. GREF R, MINAMITAKE Y, PERACCHIA MT et al.: Poly(ethylene glycol)-coated nanospheres: potential carriers for intravenous drug administration. Pharm. Biotechnol. (1997) 10:167-198.
95. GIBAUD S, ANDREUX JP, WEINGARTEN C, RENARD M, COUVREUR P: Increased bone marrow toxicity of doxorubicin bound to nanoparticles. Eur. J. Cancer (1994) 30A:820-826.
96. DEMOY M, GIBAUD S, ANDREUX JP, WEINGARTEN C, GOURITIN B, COUVREUR P: Splenic trapping of nanoparticles: complementary approaches for in situ studies. Pharm. Res. (1997) 14:463-468.
97. LEMARCHAND C, GREF R, COUVREUR P: Polysaccharide-decorated nanoparticles. Eur. J. Pharm. Biopharm (2004) 58:327-341.
98. LEMARCHAND C, GREF R, PASSIRANI C et al.: Influence of polysaccharide coating on the interactions of nanoparticles with biological systems. Biomaterials (2006) 27:108-118.
99. WEISSLEDER R, KELLY K, SUN EY, SHTATLAND T, JOSEPHSON L: Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol (2005) 23:1418-1423.
100. MOSQUEIRA VC, LEGRAND P, MORGAT JL et al.: Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density. Pharm. Res. (2001) 18:1411-1419.
101. 14C-poly (methylmethacrylate) nanoparticles in experimental tumor models. Pharm. Res. (2001) 18:1613-1619.
102. BAZILE D, PRUD'HOMME C, BASSOULLET MT, MARLARD M, SPENLEHAUER G, VEILLARD M: Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. (1995) 84:493-498.
103. SEHGAL D, VIJAY IK: A method for the high efficiency of water-soluble carbodiimide-mediated amidation. Anal. Biochem. (1994) 218:87-91.
104. TAKAE S, AKIYAMA Y, OTSUKA H, NAKAMURA T, NAGASAKI Y, KATAOKA K: Ligand density effect on biorecognition by pegylated gold nanoparticles: regulated interaction of RCA(120) lectin with lactose installed to the distal end of tethered PEG strands on gold surface. Biomacromolecules (2005) 6:818-824.
105. BRANNON-PEPPAS L, BLANCHETTE JO: Nanoparticle and targeted systems for cancer therapy. Adv. Drug Del. Rev. (2004) 56:1649-1659.
106. MONSKY WL, FUKUMURA D, GOHONGI T et al.: Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res. (1999) 59:4129-4135.
107. MAEDA H: The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. (2001) 41:189-207.
108. YUAN F, DELLIAN M, FUKUMURA D et al.: Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. (1995) 55:3752-3756.
109. KONG G, BRAUN RD, DEWHIRST MW: Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res. (2000) 60:4440-4445.
110. YUAN F, LEUNIG M, HUANG SK, BERK DA, PAPAHADJOPOULOS D, JAIN RK: Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. (1994) 54:3352-3356.
111. BAXTER LT, JAIN RK: Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. Microvasc. Res. (1991) 41:5-23.